Seres Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $25.0M | $174.8M | $116.0M |
| FY2021 | $24.1M | $131.5M | $180.0M |
| FY2022 | $50.0M | $10.8M | $163.0M |
| FY2023 | $110.0M | $-44.9M | $128.0M |
| FY2024 | — | $13.8M | $30.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $25.0M | $174.8M | $116.0M |
| FY2021 | $24.1M | $131.5M | $180.0M |
| FY2022 | $50.0M | $10.8M | $163.0M |
| FY2023 | $110.0M | $-44.9M | $128.0M |
| FY2024 | — | $13.8M | $30.8M |